Comparative Tolerability of Oral 5-HT1B/1D Agonists

This publication has 12 references indexed in Scilit:

• Rizatriptan, a Novel 5-HT1D/1B Agonist for Migraine: Single- and Multiple-Dose Tolerability and Pharmacokinetics in Healthy Subjects
  The Journal of Clinical Pharmacology, 2000
• Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
  BMJ, 1999
• Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks
  Headache: The Journal of Head and Face Pain, 1999
• Efficacy and Adverse Events of Subcutaneous, Oral, and Intranasal Sumatriptan Used for Migraine Treatment: A Systematic Review Based on Number Needed To Treat
  Cephalalgia, 1998
• Effects of the Novel High-Affinity 5-HT1B/1D-Receptor Ligand Frovatriptan in Human Isolated Basilar and Coronary Arteries
  Journal of Cardiovascular Pharmacology, 1998
• Pharmacokinetics and Pharmacodynamics of Avitriptan in Patients With Migraine After Oral Dosing
  Headache: The Journal of Head and Face Pain, 1998
• Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo‐Controlled, Outpatient Study
  Headache: The Journal of Head and Face Pain, 1998
• Naratriptan is Effective and Well Tolerated in the Acute Treatment of Migraine. Results of a Double‐Blind, Placebo‐Controlled, Parallel‐Group Study
  Headache: The Journal of Head and Face Pain, 1997
• The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)
  British Journal of Clinical Pharmacology, 1997
• The Safety and Tolerability of Sumatriptan: An Overview
  European Neurology, 1991